Table 1 Demographics and clinicopathologic features of 69 NSCLC patients screened for T790 M mutation
Variables | No. of patients (%) |
|---|---|
Gender | |
Male | 23(33.3) |
Female | 46(66.7) |
Age | |
≤ 40 | 5 (7.2) |
> 40 | 64(92.8) |
ECOG performance status | |
0–1 | 58(84.1) |
2 | 11(15.9) |
Histologic subtype | |
Adenocarcinoma | 67(97.1) |
Adenosquamous carcinoma | 2 (2.9) |
Smoking status | |
Smoker | 22(31.9) |
Non-smoker | 47(68.1) |
TNM Stage | |
IIIB | 20(29.0) |
IVA | 21(30.4) |
IVB | 28(40.6) |
M Stage | |
M1a | 19(38.8) |
M1b | 4 (8.2) |
M1c | 26(53.0) |
First generation EGFR TKIs | |
Gefitinib | 22(31.8) |
Elortinib | 15(21.7) |
Ecotinib | 31(44.9) |
Two or more TKI drugs | 1 (1.4) |
EGFR mutation detection | |
FFPE slieds by cobas | 22 |
cfDNA by cobas | 47 |
T790 M ddPCR assay | 69 |
Total | 69 |